Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

Back to Search
Print
Bookmark Trial

NCT00174239

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Westmead, New South Wales, , Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Parkinson Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Idiopathic Parkinson Disease

- Must be experiencing sleep akinesia

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Current treatment with other dopamine agonists


- Nocturnal hallucinations


- Dementia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Parkinson DiseasePF 06412562 in Subjects With Advanced Stage Parkinson's Disease
NCT03665454
  1. Hershey, Pennsylvania
ALL GENDERS
0+
years
MULTIPLE SITES
Parkinson DiseaseStudy Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
NCT00036218
  1. Hot Springs, Arkansas
  2. Little Rock, Arkansas
  3. Carmichael, California
  4. Fresno, California
  5. Irvine, California
  6. La Jolla, California
  7. Loma Linda, California
  8. Los Angeles, California
  9. Oceanside, California
  10. San Francisco, California
  11. San Francisco, California
  12. San Luis Obiapo, California
  13. Walnut Creek, California
  14. Walnut Creek, California
  15. Denver, Colorado
  16. Fairfield, Connecticut
  17. New Haven, Connecticut
  18. Wilmington, Delaware
  19. Boca Raton, Florida
  20. Clearwater, Florida
  21. Fort Lauderdale, Florida
  22. Jacksonville, Florida
  23. Jacksonville, Florida
  24. Maitland, Florida
  25. Miami, Florida
  26. Naples, Florida
  27. Orlando, Florida
  28. Palm Beach Gardens, Florida
  29. Plantation, Florida
  30. St. Petersburg, Florida
  31. Tallahassee, Florida
  32. Tampa, Florida
  33. Atlanta, Georgia
  34. Conyers, Georgia
  35. Decatur, Georgia
  36. Savannah, Georgia
  37. Chicago, Illinois
  38. Chicago, Illinois
  39. Glenbrook, Illinois
  40. Kansas City, Kansas
  41. Lake Charles, Louisiana
  42. Shreveport, Louisiana
  43. Baltimore, Maryland
  44. Columbia, Maryland
  45. Frederick, Maryland
  46. Rockville, Maryland
  47. Boston, Massachusetts
  48. Boston, Massachusetts
  49. Ann Arbor, Michigan
  50. East Lansing, Michigan
  51. Grand Rapids, Michigan
  52. Southfield, Michigan
  53. Traverse City, Michigan
  54. Golden Valley, Minnesota
  55. Minneapolis, Minnesota
  56. St. Cloud, Minnesota
  57. Kansas City, Missouri
  58. Springfield, Missouri
  59. Omaha, Nebraska
  60. Omaha, Nebraska
  61. Henderson, Nevada
  62. Lebanon, New Hampshire
  63. Morristown, New Jersey
  64. New Brunswick, New Jersey
  65. Ridgewood, New Jersey
  66. Manhasset, New York
  67. Mineola, New York
  68. Mount Vernon, New York
  69. New York, New York
  70. New York, New York
  71. New York, New York
  72. Syracuse, New York
  73. Asheville, North Carolina
  74. Raleigh, North Carolina
  75. Oklahoma City, Oklahoma
  76. Oklahoma City, Oklahoma
  77. Norristown, Pennsylvania
  78. Sellersville, Pennsylvania
  79. Upland, Pennsylvania
  80. Knoxville, Tennessee
  81. Memphis, Tennessee
  82. Nashville, Tennessee
  83. Austin, Texas
  84. Dallas, Texas
  85. Houston, Texas
  86. San Antonio, Texas
  87. Salt Lake City, Utah
  88. Burlington, Vermont
  89. Richmond, Virginia
  90. Bellevue, Washington
  91. Spokane, Washington
  92. Wenatchee, Washington
  93. Milwaukee, Wisconsin
  94. Mar Del Plata, Buenos Aires
  95. Buenos Aires, Capital Federal
  96. Buenos Aires, Capital Federal
  97. Buenos Aires,
  98. Buenos Aires,
  99. Buenos Aires,
  100. Mexico City, Mexico D.F.
  101. Monterrey, Nuevo Leon
  102. Carolina,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Parkinson DiseaseEfficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650
  1. Phoenix, Arizona
  2. Phoenix, Arizona
  3. Boca Raton, Florida
  4. Miami, Florida
  5. Tampa, Florida
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Chicago, Illinois
  11. Kansas City, Kansas
  12. Boston, Massachusetts
  13. Boston, Massachusetts
  14. Asheville, North Carolina
  15. Cleveland, Ohio
  16. Toledo, Ohio
  17. Toledo, Ohio
  18. Greenville, Texas
  19. Houston, Texas
  20. Virginia Beach, Virginia
  21. CRÉTEIL Cedex,
  22. Créteil,
  23. Grenoble,
  24. La Tronche,
  25. Marseille,
  26. Marseille,
  27. Paris,
  28. Paris,
  29. Bochum, Nordrhein-westfalen
  30. Gera,
  31. Haag I. OB,
  32. Kassel,
  33. Marburg,
  34. Tuebingen,
  35. Ulm,
  36. Holon,
  37. Holon,
ALL GENDERS
45 Years+
years
MULTIPLE SITES
Parkinson DiseaseEfficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
NCT02687542
  1. Phoenix, Arizona
  2. Phoenix, Arizona
  3. Arcadia, California
  4. Loma Linda, California
  5. Newport Beach, California
  6. Newport Beach, California
  7. Pasadena, California
  8. Torrance, California
  9. Fairfield, Connecticut
  10. Boca Raton, Florida
  11. Gainesville, Florida
  12. Ormond Beach, Florida
  13. Tampa, Florida
  14. Vero Beach, Florida
  15. Atlanta, Georgia
  16. Chicago, Illinois
  17. Indianapolis, Indiana
  18. Boston, Massachusetts
  19. Marlton, New Jersey
  20. Amherst, New York
  21. Amherst, New York
  22. Orchard Park, New York
  23. Durham, North Carolina
  24. Durham, North Carolina
  25. Raleigh, North Carolina
  26. Cleveland, Ohio
  27. Toledo, Ohio
  28. Tulsa, Oklahoma
  29. Willow Grove, Pennsylvania
  30. Providence, Rhode Island
  31. Greenville, Texas
  32. Houston, Texas
  33. Kirkland, Washington
  34. Montreal, Quebec
  35. Montreal, Quebec
  36. Grenoble,
  37. La Tronche,
  38. Lille,
  39. Marseille,
  40. Marseille,
  41. Paris,
  42. Freiburg, Baden-wuerttemberg
  43. Bochum,
  44. Dresden,
  45. Muenchen,
  46. Ulm,
  47. Asahikawa, Hokkaido
  48. Morioka, Iwate
  49. Kita-ku, Osaka
  50. Suita, Osaka
  51. Bunkyo-ku, Tokyo
  52. Santiago de Compostela, A Coruna
  53. Hospitalet de Llobregat, Barcelona
  54. San Sebastian, Guipuzcoa
  55. Barcelona,
  56. Madrid,
  57. Valencia,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Official Title  ICMJE A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.
Brief Summary The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
Detailed Description The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Parkinson Disease
Intervention  ICMJE
  • Drug: cabergoline
  • Drug: controlled-release levodopa / carbidopa
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: September 9, 2005)		220
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Idiopathic Parkinson Disease
  • Must be experiencing sleep akinesia

Exclusion Criteria:

  • Current treatment with other dopamine agonists
  • Nocturnal hallucinations
  • Dementia
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Italy,   Spain
Removed Location Countries United Kingdom
 
Administrative Information
NCT Number  ICMJE NCT00174239
Other Study ID Numbers  ICMJE A7231001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP